智通财经网·2026-01-29 09:29Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for HRS-7535 tablets, a novel oral small molecule GLP-1 receptor agonist [1] Group 1: Product Development - HRS-7535 tablets are designed to activate human GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and inhibiting gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central nervous system effects, leading to a direct reduction in energy intake [1] - Preclinical data indicates that HRS-7535 can significantly improve symptoms of chronic kidney disease (CKD) in animal models [1] Group 2: Market Context - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] - The total research and development investment for the HRS-7535 project has reached approximately 369.4 million yuan (unaudited) [1]